Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) applications for the Company’s two most advanced product candidates, AB928 and AB122. Clearance of the first IND for AB928 allows the Company to proceed with its planned Phase 1/1b trial to evaluate the safety, tolerability and preliminary efficacy of AB928 in combination with other agents, including AB122 (the Company’s anti-PD-1 antibody) and chemotherapy, in patients with breast and gynecologic malignancies. Two additional IND applications will be submitted this month which, if cleared, will enable the Company to proceed with trials of AB928 combinations in gastrointestinal malignancies, non-small cell lung cancer (NSCLC) and renal cell
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingBusiness Wire
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateBusiness Wire
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
RCUS
Earnings
- 2/21/24 - Beat
RCUS
Sec Filings
- 4/24/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- RCUS's page on the SEC website